UK-based digital health solutions provider Medopad has acquired US artificial intelligence (AI) startup Sherbit in order to enhance healthcare for patients suffering from chronic diseases.
Established in 2014, Sherbit offers data-driven technology solutions to help healthcare providers improve patient care by delivering personalised insights and recommendations.
The acquisition is intended to complement Medopad’s health technology and support its strategy to advance the healthtech ecosystem.
Medopad’s technology provides doctors with information about patients outside the hospital in real-time. This is said to improve treatment, save time and give patients more control over the disease management.
The company collaborates with healthcare organisations such as pharma companies, research institutes, insurers and technology companies to address patient monitoring challenges for rare, chronic and complex diseases.
Medopad CEO and founder Dan Vahdat said: “Acquiring Sherbit fits within our strategy to bring the healthtech ecosystem closer together, and to realise our vision to create a world where people can live longer.
“Sherbit has a strong track record of success working with some of the most prestigious healthcare organisations in the US, including the Mayo Clinic, Tufts Medical Center and Jefferson Health.
“Through this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions, reducing fragmentation and delivering at scale for Sherbit’s current and pipeline clients.”
The deal is part of Medopad’s expansion in the US, and is the first amongst its planned acquisitions.
In January this year, the company formed an alliance with US’ Johns Hopkins to leverage machine learning and patient monitoring solutions for providing better heathcare solutions.
Apart from the US market, Medopad is also boosting its footprint in China and Europe. The company previously signed various Chinese deals worth more than $140m.